Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease

Expert Opinion on Drug Safety

Volumn 9, Issue 3, 2010, Pages 379-382

  Korelitz, Burton I ^a   Reddy, Babitha ^a   Bratcher, Jason ^b  

^a LENOX HILL HOSPITAL   (United States)

^b ST VINCENT S HOSPITAL   (United States)

Author keywords

Allergies; Desensitization; Immunosuppressives; Inflammatory bowel disease

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; METHOTREXATE; PARACETAMOL; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID;

ANEMIA; COLITIS; CROHN DISEASE; DESENSITIZATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENTERITIS; ERYTHEMA; ERYTHEMA MULTIFORME; GASTROINTESTINAL TRACT; HEADACHE; HUMAN; ILEITIS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER FUNCTION TEST; LIVER INJURY; LUNG FUNCTION TEST; MONOTHERAPY; MORBIDITY; NEOPLASM; PANCREATITIS; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; REMISSION; REVIEW; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ULCERATIVE COLITIS; URTICARIA;

6-MERCAPTOPURINE; AZATHIOPRINE; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES;

EID: 77951652155     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903571626     Document Type: Review

References (23)

1. Elion GB. The significance of azathioprine metabolites. Proc R Soc Med 1972;65:257-260
2. Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000;45:1810-1813
3. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000;14:1561-1565
4. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association institute medical position statement on corticosteroid, immunomodulators, and Infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-939 (Pubitemid 43374542)
5. Sandborn W, Rutgeerts P, Renisch W, et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus asathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Presentation to the American College of Gastroenterology; 6 October 2008; Orlando, Florida
6. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127:723-729
7. Present DH, Korelitz BI, Wisch N, et al. Treatement of Crohn's disease with 6-mercaptopurine. N Engl J Med 1980;302:981-987
8. Korelitz BI, Present DH. Favorable effect of 6-mercatopurine on fistulae of Crohn's disease. Dig Dis Sci 1985;30:58-64
9. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995;12:132-142
10. Kim PS, Zlatanic J, Korelitz B, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 1999;94:3254-3257
11. Lobel EZ, Korelitz BI, Xuereb MA, et al. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol 2004;99:462-465
12. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80-85
13. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-1030
14. Warman J, Korelitz BI, Fleisher MR, et al. Cumulative experience with short-and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003;37:220-225
15. Kandiel A, Fraser AJ, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-1125
16. Saway PA, Heck LW, Bonner JR, et al. Azathioprine hypersensitivity, case report and review of the literature. Am J Med 1988;84:960-963
17. Korelitz BI, Zlatanic J, Goel F, et al. Allergic reactions to 6-mercaptopurine during the treatment of inflammatory bowel disease. J Clin Gastroenteol 1999;28:341-344
18. Mosbech H, Anderson C. Hypersensitivity of azathioprine. Ugeskr Laeg 1982;144:2424
19. Gisbert JP, Luna M, Gonzalez-Lama Y, et al. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007;102:1518-1527 (Pubitemid 46976279)
20. Panagi S, Palka W, Korelitz BI, et al. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm Bowel Dis 2004;10:274-277
21. Lee TWT, Iser JH, Gibson PR, et al. Thiopurines, a previously unrecognized cause for fatigue in patients with inflammatory bowel disease. J Crohns Colitis 2009;3:196-199
22. Mutinga M, Castells M, Horan R, et al. Successful desensitization to 6-mercaptopurine in a patient with Crohn's disease. Am J Gastroenterol 2000;5:1382-1384
23. Korelitz BI, Present DH, Rubin PH, Fochios SE. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. J Clin Gastroenterol 1984;6:27-31